Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Variations in the breast reconstruction rate in France: A nationwide study of 19,466 patients based on the French medico-administrative database.

Régis C, Le J, Chauvet MP, Le Deley MC, Le Teuff G.

Breast. 2018 Aug 6;42:74-80. doi: 10.1016/j.breast.2018.07.009. [Epub ahead of print]

PMID:
30193185
2.

High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008.

Whelan J, Le Deley MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N, Hawkins DS, Amler S, Bauer S, Bielack S, Blay JY, Burdach S, Castex MP, Dilloo D, Eggert A, Gelderblom H, Gentet JC, Hartmann W, Hassenpflug WA, Hjorth L, Jimenez M, Klingebiel T, Kontny U, Kruseova J, Ladenstein R, Laurence V, Lervat C, Marec-Berard P, Marreaud S, Michon J, Morland B, Paulussen M, Ranft A, Reichardt P, van den Berg H, Wheatley K, Judson I, Lewis I, Craft A, Juergens H, Oberlin O; Euro-E.W.I.N.G.99 and EWING-2008 Investigators.

J Clin Oncol. 2018 Sep 6:JCO2018782516. doi: 10.1200/JCO.2018.78.2516. [Epub ahead of print]

PMID:
30188789
3.

Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial.

Pannier D, Adenis A, Bogart E, Dansin E, Clisant-Delaine S, Decoupigny E, Lesoin A, Amela E, Ducornet S, Meurant JP, Le Deley MC, Penel N.

BMC Cancer. 2018 Jul 31;18(1):775. doi: 10.1186/s12885-018-4678-x.

4.

Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma.

Brodowicz T, Mir O, Wallet J, Italiano A, Blay JY, Bertucci F, Eisterer W, Chevreau C, Piperno-Neumann S, Bompas E, Ryckewaert T, Liegl-Antzwager B, Thery J, Penel N, Le Cesne A, Le Deley MC.

Eur J Cancer. 2018 Aug;99:28-36. doi: 10.1016/j.ejca.2018.05.008. Epub 2018 Jun 11.

PMID:
29902612
5.

A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial.

Lui G, Treluyer JM, Fresneau B, Piperno-Neumann S, Gaspar N, Corradini N, Gentet JC, Marec Berard P, Laurence V, Schneider P, Entz-Werle N, Pacquement H, Millot F, Taque S, Freycon C, Lervat C, Le Deley MC, Mahier Ait Oukhatar C, Brugieres L, Le Teuff G, Bouazza N; Sarcoma Group of UNICANCER.

J Clin Pharmacol. 2018 May 23. doi: 10.1002/jcph.1252. [Epub ahead of print]

PMID:
29791011
6.

Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.

Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G.

J Clin Oncol. 2018 Apr 1;36(10):951-958. doi: 10.1200/JCO.2017.76.0611. Epub 2018 Feb 7.

PMID:
29412784
7.

Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: a randomised phase III trial.

Hutt E, Da Silva A, Bogart E, Le Lay-Diomande S, Pannier D, Delaine-Clisant S, Le Deley MC, Adenis A.

BMJ Open. 2018 Jan 23;8(1):e015904. doi: 10.1136/bmjopen-2017-015904.

8.

Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.

Gaspar N, Occean BV, Pacquement H, Bompas E, Bouvier C, Brisse HJ, Castex MP, Cheurfa N, Corradini N, Delaye J, Entz-Werlé N, Gentet JC, Italiano A, Lervat C, Marec-Berard P, Mascard E, Redini F, Saumet L, Schmitt C, Tabone MD, Verite-Goulard C, Le Deley MC, Piperno-Neumann S, Brugieres L; SFCE (Société Française des Cancers de l'Enfant et l'adolescent); GSF-GETO (Groupe Sarcome Français); UNICANCER sarcoma group.

Eur J Cancer. 2018 Jan;88:57-66. doi: 10.1016/j.ejca.2017.09.036. Epub 2017 Nov 28.

PMID:
29190507
9.

Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.

Le Rhun E, Bertrand N, Dumont A, Tresch E, Le Deley MC, Mailliez A, Preusser M, Weller M, Revillion F, Bonneterre J.

Eur J Cancer. 2017 Dec;87:189-198. doi: 10.1016/j.ejca.2017.10.006. Epub 2017 Nov 2.

PMID:
29103666
10.

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.

Bahleda R, Le Deley MC, Bernard A, Chaturvedi S, Hanley M, Poterie A, Gazzah A, Varga A, Touat M, Deutsch E, Massard C, Van De Velde H, Hollebecque A, Sallansonnet-Froment M, Ricard D, Taillia H, Angevin E, Ribrag V, Soria JC.

Invest New Drugs. 2018 Aug;36(4):619-628. doi: 10.1007/s10637-017-0531-3. Epub 2017 Nov 2.

PMID:
29094232
11.

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

Massard C, Borget I, Farace F, Aspeslagh S, Le Deley MC, Le Tourneau C, Bidard FC, Pierga JY, Dieras V, Hofman P, Spano JP, Ferte C, Lacroix L, Soria JC.

Eur J Cancer. 2017 Sep;83:185-193. doi: 10.1016/j.ejca.2017.05.016. Epub 2017 Jul 22.

PMID:
28743036
12.

Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.

Tabone MD, Brugières L, Piperno-Neumann S, Selva MA, Marec-Bérard P, Pacquement H, Lervat C, Corradini N, Gentet JC, Couderc R, Chevance A, Mahier-Ait Oukhatar C, Entz-Werle N, Blay JY, Le Deley MC.

BMC Cancer. 2017 Jun 15;17(1):419. doi: 10.1186/s12885-017-3409-z.

13.

Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours.

Hollebecque A, Bahleda R, Faivre L, Adam J, Poinsignon V, Paci A, Gomez-Roca C, Thery JC, Le Deley MC, Varga A, Gazzah A, Ileana E, Gharib M, Angevin E, Malekzadeh K, Massard C, Soria JC, Spano JP.

Eur J Cancer. 2017 Aug;81:81-89. doi: 10.1016/j.ejca.2017.05.021. Epub 2017 Jun 12.

PMID:
28618305
14.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC.

Cancer Discov. 2017 Jun;7(6):586-595. doi: 10.1158/2159-8290.CD-16-1396. Epub 2017 Apr 1.

15.

Phase-II trials in osteosarcoma recurrences: A systematic review of past experience.

Omer N, Le Deley MC, Piperno-Neumann S, Marec-Berard P, Italiano A, Corradini N, Bellera C, Brugières L, Gaspar N.

Eur J Cancer. 2017 Apr;75:98-108. doi: 10.1016/j.ejca.2017.01.005. Epub 2017 Feb 20. Review.

PMID:
28219023
16.

Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).

Fresneau B, Hackshaw A, Hawkins DS, Paulussen M, Anderson JR, Judson I, Litière S, Dirksen U, Lewis I, van den Berg H, Gaspar N, Gelderblom H, Whelan J, Boddy AV, Wheatley K, Pignon JP, De Vathaire F, Le Deley MC, Le Teuff G.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26457. Epub 2017 Jan 23. Review.

PMID:
28111876
17.

Bayesian survival analysis in clinical trials: What methods are used in practice?

Brard C, Le Teuff G, Le Deley MC, Hampson LV.

Clin Trials. 2017 Feb;14(1):78-87. doi: 10.1177/1740774516673362. Epub 2016 Oct 11. Review.

PMID:
27729499
18.

Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.

Moreno L, Rubie H, Varo A, Le Deley MC, Amoroso L, Chevance A, Garaventa A, Gambart M, Bautista F, Valteau-Couanet D, Geoerger B, Vassal G, Paoletti X, Pearson AD.

Pediatr Blood Cancer. 2017 Jan;64(1):25-31. doi: 10.1002/pbc.26192. Epub 2016 Aug 24.

PMID:
27555472
19.

Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.

Piperno-Neumann S, Le Deley MC, Rédini F, Pacquement H, Marec-Bérard P, Petit P, Brisse H, Lervat C, Gentet JC, Entz-Werlé N, Italiano A, Corradini N, Bompas E, Penel N, Tabone MD, Gomez-Brouchet A, Guinebretière JM, Mascard E, Gouin F, Chevance A, Bonnet N, Blay JY, Brugières L; Sarcoma Group of UNICANCER; French Society of Pediatric Oncology (SFCE); French Sarcoma Group (GSF-GETO).

Lancet Oncol. 2016 Aug;17(8):1070-1080. doi: 10.1016/S1470-2045(16)30096-1. Epub 2016 Jun 17.

PMID:
27324280
20.

Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer.

Gouy S, Ferron G, Glehen O, Bayar A, Marchal F, Pomel C, Quenet F, Bereder JM, Le Deley MC, Morice P.

Gynecol Oncol. 2016 Aug;142(2):237-42. doi: 10.1016/j.ygyno.2016.05.032. Epub 2016 Jun 2.

PMID:
27246305
21.

Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group.

Foulon S, Brennan B, Gaspar N, Dirksen U, Jeys L, Cassoni A, Claude L, Seddon B, Marec-Berard P, Whelan J, Paulussen M, Streitbuerger A, Oberlin O, Juergens H, Grimer R, Le Deley MC.

Eur J Cancer. 2016 Jul;61:128-36. doi: 10.1016/j.ejca.2016.03.075. Epub 2016 May 10.

PMID:
27176931
22.

New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study.

Bayar MA, Le Teuff G, Michiels S, Sargent DJ, Le Deley MC.

Stat Med. 2016 Aug 30;35(19):3245-58. doi: 10.1002/sim.6942. Epub 2016 Mar 30.

PMID:
27027783
23.

Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01).

Tacher V, Le Deley MC, Hollebecque A, Deschamps F, Vielh P, Hakime A, Ileana E, Abedi-Ardekani B, Charpy C, Massard C, Rosellini S, Gajda D, Celebic A, Ferté C, Ngo-Camus M, Gouissem S, Koubi-Pick V, Andre F, Vassal G, Deandreis D, Lacroix L, Soria JC, De Baère T.

Eur J Cancer. 2016 May;59:79-89. doi: 10.1016/j.ejca.2016.02.006. Epub 2016 Mar 24.

PMID:
27017289
24.

Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.

Jovelet C, Ileana E, Le Deley MC, Motté N, Rosellini S, Romero A, Lefebvre C, Pedrero M, Pata-Merci N, Droin N, Deloger M, Massard C, Hollebecque A, Ferté C, Boichard A, Postel-Vinay S, Ngo-Camus M, De Baere T, Vielh P, Scoazec JY, Vassal G, Eggermont A, André F, Soria JC, Lacroix L.

Clin Cancer Res. 2016 Jun 15;22(12):2960-8. doi: 10.1158/1078-0432.CCR-15-2470. Epub 2016 Jan 12.

25.

Late toxicity of brachytherapy after female genital tract tumors treated during childhood: Prospective evaluation with a long-term follow-up.

Levy A, Martelli H, Fayech C, Minard-Colin V, Dumas I, Gensse MC, Le Deley MC, Oberlin O, Haie-Meder C.

Radiother Oncol. 2015 Nov;117(2):206-12. doi: 10.1016/j.radonc.2015.09.025. Epub 2015 Oct 17.

PMID:
26463838
26.

Risk of Subsequent Leukemia After a Solid Tumor in Childhood: Impact of Bone Marrow Radiation Therapy and Chemotherapy.

Allodji RS, Schwartz B, Veres C, Haddy N, Rubino C, Le Deley MC, Labbé M, Diop F, Jackson A, Dayet F, Benabdennebi A, Llanas D, Vu Bezin J, Chavaudra J, Lefkopoulos D, Deutsch E, Oberlin O, de Vathaire F, Diallo I.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):658-67. doi: 10.1016/j.ijrobp.2015.07.2270. Epub 2015 Aug 7.

PMID:
26461008
27.

Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead.

Minard-Colin V, Brugières L, Reiter A, Cairo MS, Gross TG, Woessmann W, Burkhardt B, Sandlund JT, Williams D, Pillon M, Horibe K, Auperin A, Le Deley MC, Zimmerman M, Perkins SL, Raphael M, Lamant L, Klapper W, Mussolin L, Poirel HA, Macintyre E, Damm-Welk C, Rosolen A, Patte C.

J Clin Oncol. 2015 Sep 20;33(27):2963-74. doi: 10.1200/JCO.2014.59.5827. Epub 2015 Aug 24. Review.

28.

Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.

Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, Kovar H, Grimer R, Whelan J, Claude L, Delattre O, Paulussen M, Picci P, Sundby Hall K, van den Berg H, Ladenstein R, Michon J, Hjorth L, Judson I, Luksch R, Bernstein ML, Marec-Bérard P, Brennan B, Craft AW, Womer RB, Juergens H, Oberlin O.

J Clin Oncol. 2015 Sep 20;33(27):3036-46. doi: 10.1200/JCO.2014.59.5256. Epub 2015 Aug 24. Review.

PMID:
26304893
29.

Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.

van den Berg H, Paulussen M, Le Teuff G, Judson I, Gelderblom H, Dirksen U, Brennan B, Whelan J, Ladenstein RL, Marec-Berard P, Kruseova J, Hjorth L, Kühne T, Brichard B, Wheatley K, Craft A, Juergens H, Gaspar N, Le Deley MC; Euro-EWING99 Group.

Eur J Cancer. 2015 Nov;51(16):2453-64. doi: 10.1016/j.ejca.2015.06.123. Epub 2015 Aug 10.

PMID:
26271204
30.

Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite.

Grünewald TG, Bernard V, Gilardi-Hebenstreit P, Raynal V, Surdez D, Aynaud MM, Mirabeau O, Cidre-Aranaz F, Tirode F, Zaidi S, Perot G, Jonker AH, Lucchesi C, Le Deley MC, Oberlin O, Marec-Bérard P, Véron AS, Reynaud S, Lapouble E, Boeva V, Rio Frio T, Alonso J, Bhatia S, Pierron G, Cancel-Tassin G, Cussenot O, Cox DG, Morton LM, Machiela MJ, Chanock SJ, Charnay P, Delattre O.

Nat Genet. 2015 Sep;47(9):1073-8. doi: 10.1038/ng.3363. Epub 2015 Jul 27.

31.

Primary cutaneous and subcutaneous Ewing sarcoma.

Di Giannatale A, Frezza AM, Le Deley MC, Marec-Bérard P, Benson C, Blay JY, Bui B, Judson I, Oberlin O, Whelan J, Gaspar N.

Pediatr Blood Cancer. 2015 Sep;62(9):1555-61. doi: 10.1002/pbc.25535. Epub 2015 Apr 20.

PMID:
25894676
32.

Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC.

Strullu M, Thomas C, Le Deley MC, Chevance A, Kanold J, Bertrand Y, Jubert C, Dalle JH, Paillard C, Baruchel A, Lamant L, Michel G, Brugières L.

Bone Marrow Transplant. 2015 Jun;50(6):795-801. doi: 10.1038/bmt.2015.57. Epub 2015 Mar 30.

PMID:
25822227
33.

[The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB].

Ezzalfani M, Dugué A, Mollevi C, Pulido M, Bonnetain F, Filleron T, Gal J, Gauthier M, Le Deley MC, Le Tourneau C, Médioni J, Nguyen JM, Chabaud S, Teixeira L, Thivat E, You B, Kramar A, Paoletti X.

Bull Cancer. 2015 Jan;102(1):73-82. doi: 10.1016/j.bulcan.2014.10.001. Epub 2015 Jan 2. Review. French.

PMID:
25609488
34.

A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials.

Doussau A, Thiébaut R, Geoerger B, Schöffski P, Floquet A, Le Deley MC, Mathoulin-Pélissier S, Rizzo E, Fumoleau P, Le Tourneau C, Paoletti X.

Ann Oncol. 2015 Feb;26(2):422-8. doi: 10.1093/annonc/mdu523. Epub 2014 Nov 17.

PMID:
25403589
35.

Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.

Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, Zhang Z, Lapouble E, Grossetête-Lalami S, Rusch M, Reynaud S, Rio-Frio T, Hedlund E, Wu G, Chen X, Pierron G, Oberlin O, Zaidi S, Lemmon G, Gupta P, Vadodaria B, Easton J, Gut M, Ding L, Mardis ER, Wilson RK, Shurtleff S, Laurence V, Michon J, Marec-Bérard P, Gut I, Downing J, Dyer M, Zhang J, Delattre O; St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project and the International Cancer Genome Consortium.

Cancer Discov. 2014 Nov;4(11):1342-53. doi: 10.1158/2159-8290.CD-14-0622. Epub 2014 Sep 15.

36.

Overexpression of smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma.

Lamora A, Talbot J, Bougras G, Amiaud J, Leduc M, Chesneau J, Taurelle J, Stresing V, Le Deley MC, Heymann MF, Heymann D, Redini F, Verrecchia F.

Clin Cancer Res. 2014 Oct 1;20(19):5097-112. doi: 10.1158/1078-0432.CCR-13-3191. Epub 2014 Aug 8.

37.

Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.

Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J, Le Teuff G, Michon J, Ladenstein R, Marec-Bérard P, van den Berg H, Hjorth L, Wheatley K, Judson I, Juergens H, Craft A, Oberlin O, Dirksen U.

J Clin Oncol. 2014 Aug 10;32(23):2440-8. doi: 10.1200/JCO.2013.54.4833. Epub 2014 Jun 30.

PMID:
24982464
38.

Paediatric anaplastic large cell lymphoma with leukaemic presentation in children: a report of nine French cases.

Spiegel A, Paillard C, Ducassou S, Perel Y, Plantaz D, Strullu M, Eischen A, Lutz P, Lamant L, Le Deley MC, Brugières L.

Br J Haematol. 2014 May;165(4):545-51. doi: 10.1111/bjh.12777. Epub 2014 Feb 14.

PMID:
24666317
39.

Clinical analysis and prognostic significance of haemophagocytic lymphohistiocytosis-associated anaplastic large cell lymphoma in children.

Pasqualini C, Minard-Colin V, Saada V, Lamant L, Delsol G, Patte C, Le Deley MC, Valteau-Couanet D, Brugières L.

Br J Haematol. 2014 Apr;165(1):117-125. doi: 10.1111/bjh.12728. Epub 2014 Jan 21.

PMID:
24666094
40.

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.

Di Giannatale A, Dias-Gastellier N, Devos A, Mc Hugh K, Boubaker A, Courbon F, Verschuur A, Ducassoul S, Malekzadeh K, Casanova M, Amoroso L, Chastagner P, Zwaan CM, Munzer C, Aerts I, Landman-Parker J, Riccardi R, Le Deley MC, Geoerger B, Rubie H.

Eur J Cancer. 2014 Jan;50(1):170-7. doi: 10.1016/j.ejca.2013.08.012. Epub 2013 Sep 7.

PMID:
24021349
41.

Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.

Valteau-Couanet D, Le Deley MC, Bergeron C, Ducassou S, Michon J, Rubie H, Le Teuff G, Coze C, Plantaz D, Sirvent N, Bouzy J, Chastagner P, Hartmann O.

Pediatr Blood Cancer. 2014 Jun;61(6):977-81. doi: 10.1002/pbc.24713. Epub 2013 Aug 23.

PMID:
23970413
42.

Central nervous system involvement in anaplastic large cell lymphoma in childhood: results from a multicentre European and Japanese study.

Williams D, Mori T, Reiter A, Woessman W, Rosolen A, Wrobel G, Zsiros J, Uyttebroeck A, Marky I, Le Deley MC, Brugières L; European Intergroup for Childhood Non-Hodgkin Lymphoma, the Japanese Pediatric Leukemia/Lymphoma Study Group.

Pediatr Blood Cancer. 2013 Oct;60(10):E118-21. doi: 10.1002/pbc.24591. Epub 2013 May 29.

PMID:
23720354
43.

New drugs for children and adolescents with cancer: the need for novel development pathways.

Vassal G, Zwaan CM, Ashley D, Le Deley MC, Hargrave D, Blanc P, Adamson PC.

Lancet Oncol. 2013 Mar;14(3):e117-24. doi: 10.1016/S1470-2045(13)70013-5. Epub 2013 Feb 20.

PMID:
23434337
44.

Prediction of fluid responsiveness by a continuous non-invasive assessment of arterial pressure in critically ill patients: comparison with four other dynamic indices.

Monnet X, Dres M, Ferré A, Le Teuff G, Jozwiak M, Bleibtreu A, Le Deley MC, Chemla D, Richard C, Teboul JL.

Br J Anaesth. 2012 Sep;109(3):330-8. doi: 10.1093/bja/aes182. Epub 2012 Jun 26.

45.

Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework.

Doussau A, Asselain B, Le Deley MC, Geoerger B, Doz F, Vassal G, Paoletti X.

Contemp Clin Trials. 2012 Jul;33(4):657-65. doi: 10.1016/j.cct.2011.11.015. Epub 2012 Apr 13.

PMID:
22521954
46.

Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection.

Malouf GG, Brugières L, Le Deley MC, Faivre S, Fabre M, Paradis V, Aerts I, Le Tourneau C, Dreyer C, Branchereau S, Belghiti J, Raymond E.

Cancer. 2012 Oct 15;118(20):4981-90. doi: 10.1002/cncr.27520. Epub 2012 Mar 13.

47.

Prognostic value of circulating VEGFR2+ bone marrow-derived progenitor cells in patients with advanced cancer.

Massard C, Borget I, Le Deley MC, Taylor M, Gomez-Roca C, Soria JC, Farace F.

Eur J Cancer. 2012 Jun;48(9):1354-62. doi: 10.1016/j.ejca.2012.01.021. Epub 2012 Feb 25.

PMID:
22370181
48.

Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP).

Kilday JP, Mitra B, Domerg C, Ward J, Andreiuolo F, Osteso-Ibanez T, Mauguen A, Varlet P, Le Deley MC, Lowe J, Ellison DW, Gilbertson RJ, Coyle B, Grill J, Grundy RG.

Clin Cancer Res. 2012 Apr 1;18(7):2001-11. doi: 10.1158/1078-0432.CCR-11-2489. Epub 2012 Feb 14.

49.

Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system: a multicenter study.

Dufour C, Beaugrand A, Le Deley MC, Bourdeaut F, André N, Leblond P, Bertozzi AI, Frappaz D, Rialland X, Fouyssac F, Edan C, Grill J, Quidot M, Varlet P.

Cancer. 2012 Aug 1;118(15):3812-21. doi: 10.1002/cncr.26684. Epub 2011 Dec 16.

50.

Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study.

Lamant L, McCarthy K, d'Amore E, Klapper W, Nakagawa A, Fraga M, Maldyk J, Simonitsch-Klupp I, Oschlies I, Delsol G, Mauguen A, Brugières L, Le Deley MC.

J Clin Oncol. 2011 Dec 10;29(35):4669-76. doi: 10.1200/JCO.2011.36.5411. Epub 2011 Nov 14.

PMID:
22084369

Supplemental Content

Loading ...
Support Center